Comment on Zamfir et al. Hematologic Malignancies Diagnosed in the Context of the mRNA COVID-19 Vaccination Campaign: A Report of Two Cases. Medicina 2022, 58, 874

Medicina (Kaunas). 2022 Nov 1;58(11):1575. doi: 10.3390/medicina58111575.


The SARS-CoV-2 spike protein mRNA-based vaccines have prevented countless mortality and morbidity, and have an excellent risk/benefit ratio. However, various adverse events may rarely occur after the BNT162b2 vaccine, like any other medical intervention. The COVID-19 itself and the spike protein produced endogenously by mRNA vaccines may have immunological, microenvironmental, prothrombotic, and neoplastic effects. As a contribution to the published report, we would like to share our experience regarding four cases in which myeloid neoplasms emerged following the vaccination. Conclusions: There is no doubt that vaccination could continue along the lines of established universal recommendations. Meanwhile, all hematological adverse events must be closely monitored and reported. Further efforts should be focused on the probable pathobiological mechanisms and causalities of spike protein-related toxicity and clonal myeloid disorders.

Keywords: BNT162b2; COVID-19; hematologic adverse event; leukemia; malignancy.

Publication types

  • Case Reports

MeSH terms

  • BNT162 Vaccine
  • COVID-19 Vaccines* / adverse effects
  • COVID-19* / prevention & control
  • Hematologic Neoplasms*
  • Humans
  • Immunization Programs
  • RNA, Messenger / genetics
  • SARS-CoV-2
  • Spike Glycoprotein, Coronavirus


  • BNT162 Vaccine
  • COVID-19 Vaccines
  • RNA, Messenger
  • Spike Glycoprotein, Coronavirus
  • spike protein, SARS-CoV-2

Grants and funding

This research received no external funding.